Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LB-100||LB100|LB 100||PP2A Inhibitor 2||LB100 is a small molecule that inhibits PP2A activity, resulting in increased sensitivity of tumor cells to DNA damaging agents, including chemotherapy and radiotherapy (PMID: 25376608, PMID: 31935881, PMID: 30679389, PMID: 32342332).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||glioblastoma||not applicable||LB-100||Preclinical||Actionable||In a preclinical study, glioblastoma cells treated with a combination of LB100 and radiotherapy resulted in inhibition of Pp2a activity, decreased tumor growth, and increased cell survival (PMID: 25939762).||25939762|
|Unknown unknown||Advanced Solid Tumor||not applicable||LB-100||Phase I||Actionable||In a Phase I trial, LB-100 demonstrated safety and preliminary clinical activity in patients with advanced solid tumors, including a partial response in a pancreatic cancer patient, and stable disease for at least 4 cycles in 50% (10/20) of patients (PMID: 28039265; NCT01837667).||28039265|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03027388||Phase I||LB-100||Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma||Recruiting||USA||0|
|NCT03886662||Phase Ib/II||LB-100||A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)||Recruiting||USA||0|